NanoViricides is trading 6.02% higher in pre-market at $1.59 after enrollment and dosing began in its Phase II oral NV-387 Ebola trial. - It closed at $1.50 on September 28. - First patients were dosed around September 23 at a treatment center in Ituri province, Democratic Republic of Congo. - No separate September 29 announcement was identified; broader markets were mixed, and pre-market volume and activity data were unavailable in cited sources.